Method for preparing antibody-containing formulation
The present invention provides a pharmaceutical formulation that reduces formation of particles including an anti-IL-6 receptor antibody that inhibits binding with a receptor for interleukin 6 or an anti-blood coagulation factor IXa/X antibody (bispecific monoclonal antibody) used as a substitution...
Saved in:
Main Authors | , , , , , , , , , |
---|---|
Format | Patent |
Language | Chinese English |
Published |
01.09.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention provides a pharmaceutical formulation that reduces formation of particles including an anti-IL-6 receptor antibody that inhibits binding with a receptor for interleukin 6 or an anti-blood coagulation factor IXa/X antibody (bispecific monoclonal antibody) used as a substitution for coagulation factor VIII. The provided pharmaceutical formulation includes an aqueous solution containing a polyoxyethylene polyoxypropylene glycol (poloxamer). The poloxamer is represented by formula I: HO(C2H4O)a(C3H6O)b(C2H4O)cH [in the formula, a and c each independently represent an integer selected from 75-85, b represents an integer selected from 22-33, and a, b, and c are each an average with respect to the whole of the poloxamer]. The poloxamer contains a poloxamer molecule including 34 or more of (C3H6O) within the molecule, at a proportion of 3%(w/w) or more with respect to the whole poloxamer. |
---|---|
Bibliography: | Application Number: TW202211146149 |